HEMOSOL , Heute 1$ ?

After Hours Bid .84 ask .85??  
buy
Long-Term Sentiment: Strong Buy  09/22/03 06:32 pm


Buyout rumor. HMSL should hit $1 tomorrow.
Yeahhhhhh!

Die geht heute ab wie eine Rakete.

CIAO  

CIAO  

hier sind wir lange noch nicht fertig. Kurse AH 0,85 $

CIAO  

teile doch mal mit, was für die Aktie spricht. Also warum der Wert steigt. Kann ja jeder sagen "Noch lange nicht fertig...", aber warum ?  

rloren. Womit sich der CEO Kennedy eigentlich in den letzten 2 Jahren sein Gehalt gezahlt hat und womit die "Zulassung" von dem Homolink oder wie das Zeug nochmal hies, betrieben wurde ist mir rätzelhaft.
Aber kaufen würd ich die erst, wenn ich schwarz auf weis  in mehreren Zeitungen nachlesen könnte, das den ihr Mittel nun entlich in USA zugelassen wäre.
Höchste Vorsicht, hier wird doch sicher wieder nur ein übles Spielchen getrieben.

Pieter  

Viele halten nichts von Charttechnik aber trotzdem :

Composite Indicator -- Signal -- -- Strength -- -- Direction --
Trend Spotter (TM) Buy Weak Strongest

Short Term Indicators
7 Day Average Directional Indicator Buy Average Strongest
10 - 8 Day Moving Average Hilo Channel Buy Weak Strongest
20 Day Moving Average vs Price Buy Weak Strongest
20 - 50 Day MACD Oscillator Buy Minimum Strongest
20 Day Bollinger Bands Buy Average Strongest

Short Term Indicators Average: 100% - Buy

Medium Term Indicators
40 Day Commodity Channel Index Buy Strong Strongest
50 Day Moving Average vs Price Buy Weak Strongest
20 - 100 Day MACD Oscillator Buy Minimum Average
50 Day Parabolic Time/Price Buy Weak Strongest

Medium Term Indicators Average: 100% - Buy

Long Term Indicators
60 Day Commodity Channel Index Buy Average Strongest
100 Day Moving Average vs Price Buy Weak Strongest
50 - 100 Day MACD Oscillator Buy Minimum Average

Long Term Indicators Average: 100% - Buy

Overall Average: 100% - Buy

Bei dem Volumen sind sicherlich gute News im Anmarsch,weil einige Leute immer mehr wissen als andere.

CIAO
 

wenn sie dieses Patent bekommen ?      ( letzter Satz )


HRC 304 - Blood Cell Production
Hemosol Research Corporation Ltd. (HRC) scientists have recently discovered that stem cells possess a novel activation pathway that may play a role in blood cell production. Stimulation of stem cells via this pathway in vitro produces an increase in the growth of red blood cell and white blood cell progenitors.

Treatment of Anemia and Other Cytopenias
The discovery of a new stem cell activation pathway offers HRC the opportunity to develop novel therapeutics for the treatment of anemia. At present, erythropoietin (Epo) is the most well known therapeutic cytokine used for the treatment of anemia, acting through the selective stimulation of red blood cell production. Epo has an established North American market on the order of $1 B (USD) and is widely held as the gold standard for biotechnology companies in terms of both drug development and corporate success. Other cytokines have been developed for stimulating blood cell formation but none compare with the success of Epo (or its newer long acting version, darbepoietin). Even so, many patients, particularly those experiencing anemia while undergoing chemotherapy for the treatment of cancer and those with anemia of chronic disease, do not respond to Epo.

Clearly, an alternative pathway for stimulating the production of red blood cells, and potentially even white blood cells, offers tremendous opportunity for the development of new drugs in a large, proven market with an important medical need. HRC's expertise in stem cell research places it in good position to capitalize on this important new discovery.

Intellectual Property Covering HRC 304
Patent applications are pending.  

CIAO